In this article, Roswitha examines why less than 0.5% of healthcare VC reaches women's health and how funding structure shapes femtech validation rigor and investor trust.

Roswitha Verwer shares why YON E is closing its seed readiness round, how funding will support prototype completion, clinical trial preparation, regulatory readiness, and the next phase of women’s health diagnostics.